Expertise in
14
conditions

Dr. Sarada Gurubhagavatula

Hematology Oncology | Oncology | Hematology
Summit Medical Group PA
1 Diamond Hill Rd, 
Berkeley Heights, NJ 
 (2838.5 mi)
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
14
conditions
Summit Medical Group PA
1 Diamond Hill Rd, 
Berkeley Heights, NJ 
 (2838.5 mi)
OverviewInsuranceLocationsClinical Research

Overview

Sarada Gurubhagavatula is a Hematologist Oncology specialist and an Oncologist in Berkeley Heights, New Jersey. Dr. Gurubhagavatula is highly rated in 14 conditions, according to our data. Her top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, and Familial Pancreatic Cancer. Dr. Gurubhagavatula is currently accepting new patients.

Her clinical research consists of participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in NJ
Hospital Affiliations
Cooperman Barnabas Medical Center
Morristown Medical Center
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Humana

Locations

SUMMIT MEDICAL GROUP PA
1 Diamond Hill Rd, Berkeley Heights, NJ 07922

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Collection of Sputum and Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer
Collection of Sputum and Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer
Enrollment Status: Recruiting
Publish Date: July 27, 2023
Induction Durvalumab Followed by Chemoradiation and Consolidation Durvalumab (MEDI4736) for Stage III Non-small Cell Lung Cancer
Induction Durvalumab Followed by Chemoradiation and Consolidation Durvalumab (MEDI4736) for Stage III Non-small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: December 20, 2024
Intervention Type: Drug, Radiation
Study Drugs: Durvalumab, Chemotherapy
Study Phase: Phase 2
An Open-Label Randomized Phase II Study of Combining Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor (TKI)-naïve Epidermal Growth Factor Receptor (EGFR)-Mutant Locally Advanced or Metastatic NSCLC
An Open-Label Randomized Phase II Study of Combining Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor (TKI)-naïve Epidermal Growth Factor Receptor (EGFR)-Mutant Locally Advanced or Metastatic NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: October 30, 2024
Intervention Type: Drug
Study Drugs: Osimertinib, Ramucirumab
Study Phase: Phase 2
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: GC4419
Study Phase: Phase 3
A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib Versus Placebo in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated With Docetaxel in the 2nd/3rd Line Setting (PRESERVE 4)
A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib Versus Placebo in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated With Docetaxel in the 2nd/3rd Line Setting (PRESERVE 4)
Enrollment Status: Terminated
Publish Date: April 14, 2023
Intervention Type: Drug
Study Drugs: Trilaciclib, Docetaxel
Study Phase: Phase 2
Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
Enrollment Status: Terminated
Publish Date: May 06, 2022
Intervention Type: Drug
Study Drugs: Trilaciclib, Carboplatin, Etoposide, Atezolizumab
Study Phase: Phase 2
Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus Cyclophosphamide, Doxorubicin and Vincristine (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS)
Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus Cyclophosphamide, Doxorubicin and Vincristine (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS)
Enrollment Status: Completed
Publish Date: October 28, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 6 Less Clinical Trials
Similar Doctors
Expertise in
16
conditions
Dr. Andrew M. Evens
Hematology | Hematology Oncology | Oncology
Expertise in
16
conditions
Dr. Andrew M. Evens
Hematology | Hematology Oncology | Oncology

Rutgers Health-Rwj Scleroderma Program

1 Robert Wood Johnson Pl, Rutgers Health Rwj Cancer Institute, 
New Brunswick, NJ 
 (12.7 mi)
732-828-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Evens is a Hematologist and a Hematologist Oncology provider in New Brunswick, New Jersey. Dr. Evens is highly rated in 16 conditions, according to our data. His top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Evens is currently accepting new patients.

Expertise in
27
conditions
Dr. Matthew J. Matasar
Oncology | Hematology Oncology | Hematology
Expertise in
27
conditions
Dr. Matthew J. Matasar
Oncology | Hematology Oncology | Hematology

Rutgers Health-Rwj Scleroderma Program

195 Little Albany St, 
New Brunswick, NJ 
 (12.6 mi)
732-235-2465
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Matthew Matasar is an Oncologist and a Hematologist Oncology provider in New Brunswick, New Jersey. Dr. Matasar is highly rated in 27 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, B-Cell Lymphoma, and Bone Marrow Transplant. Dr. Matasar is currently accepting new patients.

Richard R. Furman
Expertise in
47
conditions
Dr. Richard R. Furman
Hematology | Oncology | Hematology Oncology
Expertise in
47
conditions
Dr. Richard R. Furman
Hematology | Oncology | Hematology Oncology

Weill Medical College Of Cornell

520 E 70th St, Suite 651, 
New York, NY 
 (24.7 mi)
212-746-6575
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Richard Furman is a Hematologist and an Oncologist in New York, New York. Dr. Furman is highly rated in 47 conditions, according to our data. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Richter Syndrome, Bone Marrow Aspiration, and Lymphadenectomy.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile